ERK and p38 MAPK activities determine sensitivity to PI3K/mTOR inhibition via regulation of MYC and YAP

Aberrant activation of the PI3K/mTOR-pathway is a common feature of many cancers and an attractive target for therapy, but resistance inevitably evolves is as the case for any cancer cell targeted therapy. In animal tumor models, chronic inhibition of PI3K/mTOR initially inhibits tumor growth, but o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Muranen, Taru, Selfors, Laura M., Hwang, Julie, Gallegos, Lisa L., Coloff, Jonathan L., Thoreen, Carson C., Kang, Seong A., Sabatini, David M., Mills, Gordon B., Brugge, Joan S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161652/
https://ncbi.nlm.nih.gov/pubmed/27913436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0155
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares